Arvinas Inc (ARVN) - Total Liabilities
Based on the latest financial reports, Arvinas Inc (ARVN) has total liabilities worth $284.00 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ARVN net assets growth trend to track the company's year-over-year net asset growth rate.
Arvinas Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Arvinas Inc's total liabilities have evolved over time, based on quarterly financial data. See ARVN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Arvinas Inc Competitors by Total Liabilities
The table below lists competitors of Arvinas Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PlayAGS Inc
NYSE:AGS
|
USA | $592.31 Million |
|
Karat Packaging Inc
NASDAQ:KRT
|
USA | $141.25 Million |
|
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
|
China | CN¥116.97 Million |
|
Lu Thai Textile Co Ltd
SHE:000726
|
China | CN¥4.10 Billion |
|
Shanghai Sheng Jian Environment Technology Co Ltd
SHG:603324
|
China | CN¥1.72 Billion |
|
Potbelly Co
NASDAQ:PBPB
|
USA | $204.14 Million |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
|
China | CN¥226.79 Million |
|
Bank Maspion Indonesia PT
JK:BMAS
|
Indonesia | Rp18.62 Trillion |
Liability Composition Analysis (2016–2025)
This chart breaks down Arvinas Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Arvinas Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arvinas Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arvinas Inc (2016–2025)
The table below shows the annual total liabilities of Arvinas Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $284.00 Million | -46.38% |
| 2024-12-31 | $529.70 Million | -17.83% |
| 2023-12-31 | $644.60 Million | -8.42% |
| 2022-12-31 | $703.90 Million | -12.00% |
| 2021-12-31 | $799.90 Million | +963.70% |
| 2020-12-31 | $75.20 Million | +0.33% |
| 2019-12-31 | $74.96 Million | +19.71% |
| 2018-12-31 | $62.61 Million | -5.99% |
| 2017-12-31 | $66.60 Million | +378.96% |
| 2016-12-31 | $13.91 Million | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more